Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma
Highly Entrenched Rituxan Could Prove Tough To Dislodge
Executive Summary
Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.
You may also be interested in...
Precision’s Allo CAR-T Inches Closer To Filling Post-Auto CAR-T Niche
The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.
ASH Preview: Three Areas To Watch In Hematology-Oncology
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
IGM Thinks Outside Oncology Box With Anti-Infective, Autoimmune Play
The company created two new divisions focused on the new disease areas, bringing in former executives from Bristol Myers Squibb and Sanofi Pasteur.